MD Anderson Acquires Inducible Switch Technologies for Cell Therapy
February 23, 2024
February 23, 2024
HOUSTON, Texas, Feb. 23 (TNSres) -- The University of Texas's MD Anderson Cancer Center issued the following news release:
The University of Texas MD Anderson Cancer Center today announced it has acquired certain assets from Bellicum Pharmaceuticals, Inc. related to the CaspaCIDe(R) switch platform and the GoCAR(R) platform. The transaction also includes clinical-grade stocks of rimiducid, an agent used to trigger the switches.
As a result of this acquisition, MD Anders . . .
The University of Texas MD Anderson Cancer Center today announced it has acquired certain assets from Bellicum Pharmaceuticals, Inc. related to the CaspaCIDe(R) switch platform and the GoCAR(R) platform. The transaction also includes clinical-grade stocks of rimiducid, an agent used to trigger the switches.
As a result of this acquisition, MD Anders . . .